Isofol expands the number of study sites to accelerate patient recruitment in cancer study
GOTHENBURG, Sweden, August 24, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company includes additional clinical […]
mfn-cus-arfolitixorin
Isofol initiates last dose cohort in ongoing phase Ib study with arfolitixorin
GOTHENBURG, Sweden, July 8, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed
Isofol Medical AB (publ) publishes interim report, January – March 2026
GOTHENBURG, Sweden, May 19, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
Isofol optimizes the design of its phase Ib/II study following new regulatory approval
GOTHENBURG, Sweden, April 15, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the German regulatory authority
Isofol Medical AB (publ) publishes annual report and corporate governance report for 2025
GOTHENBURG, Sweden, April 10, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announced that the company’s annual report
Isofol presents at investor meetings in March
GOTHENBURG, Sweden, March 3, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company will participate
Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin
GOTHENBURG, Sweden, February 24, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company’s
Isofol Medical AB (publ) publishes year-end report, January – December 2025
GOTHENBURG, Sweden, February 18, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
Isofol participates in the ASCO GI congress
GOTHENBURG, Sweden, January 9, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company will participate